In 2011, Cephalon agreed to acquire ChemGenex Pharmaceuticals, which would provided Cephalon with marketing rights to Omapro, a therapeutic agent for a drug-resistant leukemia, in the oncology …

Cephalon Inc. was established in 1987 as a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals...

Information on acquisition, funding, cap tables, investors, and executives for Cephalon. Use the PitchBook Platform to explore the full profile.

Cephalon, Inc. is an international biopharmaceutical company that specializes in drugs to treat neurological and sleep disorders. The company's activities encompass the discovery, research, and …

Company profile page for Cephalon Inc including stock price, company news, executives, board members, and contact information

Feb 8, 2026 · Discover Company Info on CEPHALON, INC. in Chicago, IL, such as Contacts, Addresses, Reviews, and Registered Agent.

Mar 27, 2001 · Cephalon's business strategy is to pursue the development and commercialization of novel therapeutic products for the treatment of neurological diseases, sleep disorders and cancer.

Get insights into Cephalon, Inc. including business profile, stock information, news, and rankings from Fortune.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central …

Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., [1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three …